Cell Differentiation Hub operates at the intersection of rigorous science and pragmatic commercialisation. Our approach is built on a reproducible research platform, a disciplined translation pathway, and a dual-track business model that generates value from both proprietary therapies and licensed technologies.
CDH is actively developing its own extracellular vesicles (EVs) derived from Plants, that are Therapeutically proven by traditional medicine, utilising cutting-edge technologies, enabling large-scale production.
Our development goals include:
Exosomes are tiny vesicles secreted by cells that play a crucial role in cell communication and tissue regeneration. These extracellular vesicles contain various bioactive molecules such as proteins, lipids, and nucleic acids, which can influence neighbouring cells and tissues. We have been working on plant exosomes and exploring the therapeutic potential of exosomes derived from plants, harnessing their natural properties for cosmetic applications.
We are currently engaged in Therapeutic research in Skin Care. A concurrent line of research is into other possibilities that selective plant-based EVs could be formulated to treat, reducing healthcare conditions. One line of work we are aiming to complete is in eye-care, oncology and arthritis segments, paediatric AD and pet skin care products.
Cell Differentiation Hub was founded on a single conviction: that the gap between fundamental stem cell discovery and patient-available therapy can be closed systematically, without sacrificing scientific rigour for commercial speed, or commercial pragmatism for scientific ambition. We believe the two are complementary, not competing.
Our methodology integrates continuous feedback between the laboratory bench, the clinical interface, and the commercial development team. Every research programme is assessed not only for biological validity but for manufacturability, regulatory navigability, and health-economic justification from its earliest stages — eliminating costly late-stage pivots that erode timelines and capital.
"We do not translate science into products. We design products from the first moment of scientific inquiry."
Cell Differentiation Hub Research Principles, 2024 EditionCell Differentiation Hub Integrated Value Model
Our research and development methodology is structured around four interdependent pillars. Each pillar is a discipline in its own right, and together they form a coherent system designed to move candidate therapies from early discovery to regulatory submission with minimum attrition and maximum scientific integrity.
All research programmes originate on a shared human exosome, iPSC, MSC and plant-based exosome reprogramming platform, ensuring cross-product knowledge transfer, shared reagent economics, and regulatory consistency across the pipeline. No programme is initiated as a standalone — each is designed to strengthen the platform.
Cell therapy candidates are evaluated for GMP manufacturability at the point of target selection — not at the point of clinical entry. Process development runs in parallel with efficacy studies, and scale-up parameters are embedded in every protocol from day one.
Clinical translation partners are engaged during preclinical stage II, not post-IND. This early integration ensures that study designs reflect clinical practice realities, endpoint selection reflects payer expectations, and patient recruitment strategies are operational before regulatory submission.
Every programme passes through predefined scientific and commercial decision gates at each stage transition. These gates are not milestones — they are structured kill/accelerate decisions based on pre-agreed criteria, ensuring capital is reallocated rapidly when a programme underperforms.
Our five-stage translation pathway is not a linear conveyor belt but a structured feedback loop. Insights from later stages actively reshape earlier-stage work, ensuring that our research platform continuously improves with each programme that advances through it.
A dedicated Translational Operations team manages stage transitions, maintains regulatory documentation continuously rather than retrospectively, and engages health technology assessment bodies from Stage 3 onwards — ensuring market access considerations are never an afterthought.
Cell Differentiation Hub generates value through two complementary and reinforcing revenue tracks. The first is the direct development and commercialisation of proprietary cell therapies, which we take from discovery through regulatory approval and to market under our own label or through carefully selected distribution partners. The second is the licensing of our underlying cell programming platform technologies — the iPSC reprogramming protocols, GMP bioreactor processes, characterisation assay suites, and delivery formulation know-how — to pharmaceutical and biotechnology companies that wish to accelerate their own cell therapy programmes without building equivalent infrastructure.
These two tracks are not in competition. Licensing revenue from the platform funds the capital-intensive late-stage clinical development of proprietary therapies, while proprietary therapy success generates platform validation data that enhances the licensing proposition. Together, they create a self-reinforcing model that reduces dependence on any single revenue event and provides downside protection during the inherently uncertain clinical development period.
We develop, manufacture, and commercialise cell therapies under our own label for conditions where we hold a defensible IP position and where the clinical path is well-defined. These therapies are sold directly to hospital and clinic procurement channels or via regional distribution partnerships in markets where we do not hold a direct commercial presence.
Our core technology platform — encompassing exosomes, iPSC reprogramming, GMP expansion bioreactors, potency assay suites, and plant-based exosome formulation know-how — is available to pharma and biotech partners under structured licensing agreements. Licences are structured as upfront access fees, milestone payments triggered by partner programme events, and royalties on net sales of products using the licensed technology.
For selected indications where a pharma partner brings complementary assets — such as delivery device expertise, established clinical networks, or existing regulatory approvals in adjacent areas — we enter co-development agreements. These are structured as jointly-funded programmes with pre-agreed commercial rights splits, reducing our capital exposure on high-cost late-stage programmes while preserving meaningful economics on successful outcomes.
"Licensing revenue is not a fallback when therapy development struggles — it is a deliberate and equal contributor to the financial architecture of the company, designed to run in parallel from the outset."
Cell Differentiation Hub Commercial Strategy FrameworkBeyond patents, Cell Differentiation Hub maintains significant trade secret protections across manufacturing process know-how and quality control protocols. These trade secrets represent meaningful barriers to replication that persist beyond patent expiry, and they form a substantial component of the value proposition offered to licensing partners.
Cell Differentiation Hub does not operate as a standalone entity. Our research, clinical, and commercial activities are deeply embedded in a network of academic medical centres, contract development and manufacturing organisations, regulatory consultancies, and pharmaceutical companies. This ecosystem provides surge capacity, specialist expertise, and market access capabilities that would be disproportionately expensive to replicate internally.
Partnership agreements are structured to create mutual dependency — our partners gain early access to platform technologies and clinical data; we gain manufacturing capacity, clinical infrastructure, and geographic distribution reach. Exclusivity provisions are programme-specific and time-limited, preserving strategic flexibility as the portfolio matures.
"We are selective about partners precisely because selectivity is what makes the partnerships valuable."
Cell Differentiation Hub Partnership PrinciplesWhether you are interested in licensing our platform technologies, co-developing a therapy programme, or understanding how our methodology could accelerate your pipeline, we welcome the conversation.